Antibody data
- Antibody Data
- Antigen structure
- References [5]
- Comments [0]
- Validations
- Western blot [2]
- ELISA [1]
Submit
Validation data
Reference
Comment
Report error
- Product number
- ABIN393627 - Provider product page
- Provider
- antibodies-online
- Product name
- anti-Cyclin-Dependent Kinase 4 (CDK4) (AA 211-304) antibody
- Antibody type
- Monoclonal
- Description
- This antibody is purified through a protein G column, eluted with high and low pH buffers and neutralized immediately, followed by dialysis against PBS.
- Reactivity
- Human, Mouse
- Host
- Mouse
- Epitope
- AA 211-304
- Isotype
- IgG
- Antibody clone number
- 2G7
- Vial size
- 100 μg
- Storage
- Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles
Submitted references The Ras oncogene signals centrosome amplification in mammary epithelial cells through cyclin D1/Cdk4 and Nek2.
Variation at the NFATC2 locus increases the risk of thiazolidinedione-induced edema in the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) study.
Pattern of retinoblastoma pathway inactivation dictates response to CDK4/6 inhibition in GBM.
A Large-scale genetic association study of esophageal adenocarcinoma risk.
Pharmacologic inhibition of cyclin-dependent kinases 4 and 6 arrests the growth of glioblastoma multiforme intracranial xenografts.
Zeng X, Shaikh FY, Harrison MK, Adon AM, Trimboli AJ, Carroll KA, Sharma N, Timmers C, Chodosh LA, Leone G, Saavedra HI
Oncogene 2010 Sep 9;29(36):5103-12
Oncogene 2010 Sep 9;29(36):5103-12
Variation at the NFATC2 locus increases the risk of thiazolidinedione-induced edema in the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) study.
Bailey SD, Xie C, Do R, Montpetit A, Diaz R, Mohan V, Keavney B, Yusuf S, Gerstein HC, Engert JC, Anand S, DREAM investigators.
Diabetes care 2010 Oct;33(10):2250-3
Diabetes care 2010 Oct;33(10):2250-3
Pattern of retinoblastoma pathway inactivation dictates response to CDK4/6 inhibition in GBM.
Wiedemeyer WR, Dunn IF, Quayle SN, Zhang J, Chheda MG, Dunn GP, Zhuang L, Rosenbluh J, Chen S, Xiao Y, Shapiro GI, Hahn WC, Chin L
Proceedings of the National Academy of Sciences of the United States of America 2010 Jun 22;107(25):11501-6
Proceedings of the National Academy of Sciences of the United States of America 2010 Jun 22;107(25):11501-6
A Large-scale genetic association study of esophageal adenocarcinoma risk.
Liu CY, Wu MC, Chen F, Ter-Minassian M, Asomaning K, Zhai R, Wang Z, Su L, Heist RS, Kulke MH, Lin X, Liu G, Christiani DC
Carcinogenesis 2010 Jul;31(7):1259-63
Carcinogenesis 2010 Jul;31(7):1259-63
Pharmacologic inhibition of cyclin-dependent kinases 4 and 6 arrests the growth of glioblastoma multiforme intracranial xenografts.
Michaud K, Solomon DA, Oermann E, Kim JS, Zhong WZ, Prados MD, Ozawa T, James CD, Waldman T
Cancer research 2010 Apr 15;70(8):3228-38
Cancer research 2010 Apr 15;70(8):3228-38
No comments: Submit comment
Supportive validation
- Submitted by
- antibodies-online (provider)
- Main image
- Experimental details
- WB
- Submitted by
- antibodies-online (provider)
- Main image
- Experimental details
- WB
Supportive validation
- Submitted by
- antibodies-online (provider)
- Main image
- Experimental details
- ELISA